CHICAGO–(BUSINESS WIRE)–GE HealthCare (Nasdaq: GEHC) is announcing that members of its management team will present at Citi’s 2025 Medtech and Life Sciences Access Day on February 27, 2025 at 2:15pm CT / 3:15 pm ET.
A webcast of this event can be accessed at the GE HealthCare website: https://investor.gehealthcare.com/news-events/events on the date and time listed above.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits.
Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.
Contacts
GE HealthCare Investor Contact:
Carolynne Borders
(631) 662-4317
carolynne.borders@gehealthcare.com
GE HealthCare Media Contact:
Jennifer Fox
(414) 530-3027
jennifer.r.fox@gehealthcare.com
SHANGHAI, March 30, 2025 /PRNewswire/ -- As the clear aligner business enters the second quarter of 2025,…
Preliminary data from Cohort 4 of the ENSURE study supports a novel enrichment strategy to…
--Data presented at the American College of Cardiology Annual Scientific Session show that the reduction…
Discover the Oral Probiotic That’s Reshaping Dental Health—Backed by 75,000+ Users and Groundbreaking Science ProDentim…
Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2…
– Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
